Search Results 1101-1110 of 13928 for Assay

1. Phase 2 Study To Evaluate The Oral Combination Of Ixazomib (MLN9708) With Cyclophosphamide And Dexamethasone In Patients With Newly Diagnosed Or Relapsed And/or Refractory Multiple Myeloma - Mayo Clinic

   Serum free light chain assay: involved free light chain level ≥ 10 mg/dL (≥ 100 mg/L), provided that the serum free light chain ratio is abnormal.

2. Mycobacterium Avium Complex Pulmonary Infections Systems Biology to Predict Progression and Treatment - Mayo Clinic

   Asymptomatic subjects with diagnosis of LTBI that includes a positive results of a QuantiFERON Gold Plus test or similar Interferon-γ release assay AND a ...

3. AZD5305 Vs Placebo In Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents - Mayo Clinic

   ... assay (tissue or ctDNA) is sufficient irrespective of the result of the other assay;. Participants will be considered eligible for the Non-HRRm Cohort if no ...

4. Alternate Doses and Dosing Schedules of Belantamab Mafodotin for the Treatment of Triple-Class Recurrent and/or Refractory Multiple Myeloma - Mayo Clinic

   - Serum free light chain (FLC) assay: Involved FLC level >= 10 mg/dL (>= 100 mg/L) and an abnormal serum free light chain ratio (< 0.26 or > 1.65) - Note ...

5. A Study Of MCLA-128 In Patients With Solid Tumors Harboring An NRG1 Fusion - Mayo Clinic

   ... assays such as PCR, next generation sequencing-based assays [DNA or RNA], or FISH as routinely performed at CLIA or other similarly-certified laboratories.

6. Lenalidomide And Dexamethasone With Or Without Anakinra In Treating Patients With Early Stage Multiple Myeloma - Mayo Clinic

   Abnormal serum free light chain (FLC) ratio (< 0.26 or > 1.65) by serum FLC assay AND; Monotypic Plasma Cell S-phase ≥0.3%. Measurable level of M-protein > 1 ...

7. A Study Of Napabucasin Plus Nab-Paclitaxel With Gemcitabine In Adult Patients With Metastatic Pancreatic Adenocarcinoma - Mayo Clinic

   ... assays (Correlative Studies) of this protocol may be conducted. Submission of the tissue does not have to occur prior to randomization. Where local center ...

8. Phase Ib Study of Axatilimab in Combination with Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer - Mayo Clinic

   ... assay at the time of screening and for at least 12 weeks before screening. * c. It is advised that participants must not have had any AIDS-defining ...

9. Spatial Multiomics Core - Mayo Clinic Research Core Facilities

   Human or mouse whole-transcriptome profiling is complemented with more than 570 photocleavable, oligonucleotide-tagged antibody targets that can be assayed in ...

10. Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (ReSPECT) - Mayo Clinic

    Positive baseline serum Platelia GM EIA (≥ 0.5) and/or ?-D glucan assay (Fungitell ≥80 picograms \[pg\]/mL or Fujifilm Wako \>11 pg/mL) within 15 days ...